All Wales Medicines Strategy Group

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA373)

NICE GUIDANCE ISSUED DECEMBER 2015

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

Final Appraisal Recommendation

Advice No: 0114 – January 2014

Abatacept (Orencia®)
250 mg powder for concentrate for solution for infusion

Submission by Bristol-Myers Squibb Pharmaceuticals Ltd

Recommendation of AWMSG

Abatacept (Orencia®) is recommended as an option for use within NHS Wales in combination with methotrexate for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis in paediatric patients 6 years of age and older who have had an insufficient response to other disease-modifying anti-rheumatic drugs including at least one tumour necrosis factor inhibitor.

This recommendation applies only in circumstances where the approved Patients Access Scheme is utilised.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 002), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by the Minister for Health and Social Services and will be considered for review in three years.

Marketing authorisation holder on first issue:	Bristol-Myers Squibb Pharmaceuticals Ltd
Date of first issue	January 2014
Last reviewed	February 2017